Top

Published in:

01-02-2010 | Epidemiology

Impact of obesity on diagnosis and treatment of breast cancer

Authors: Carole Deglise, Christine Bouchardy, Mafalda Burri, Massimo Usel, Isabelle Neyroud-Caspar, Georges Vlastos, Pierre Olivier Chappuis, Michela Ceschi, Silvia Ess, Monica Castiglione, Elisabetta Rapiti, Helena Marieke Verkooijen

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

In this population-based study, we evaluated the impact of obesity on presentation, diagnosis and treatment of breast cancer. Among all women diagnosed with invasive breast cancer in the canton Geneva (Switzerland) between 2003 and 2005, we identified those with information on body mass index (BMI) and categorized them into normal/underweight (BMI <25 kg/m²), overweight (BMI ≥–<30 kg/m²) and obese (BMI ≥30 kg/m²) women. Using multivariate logistic regression, we compared tumour, diagnosis and treatment characteristics between groups. Obese women presented significantly more often with stage III–IV disease (adjusted odds ratio [OR_adj]: 1.8, 95% CI: 1.0–3.3). Tumours ≥1 cm and pN2-N3 lymph nodes were significantly more often impalpable in obese than in normal/underweight patients (OR_adj 2.4, [1.1–5.3] and OR_adj 5.1, [1.0–25.4], respectively). Obese women were less likely to have undergone ultrasound (OR_adj 0.5, [0.3–0.9]) and MRI (OR_adj 0.3, [0.1–0.6]) and were at increased risk of prolonged hospital stay (OR_adj 4.7, [2.0–10.9]). This study finds important diagnostic and therapeutic differences between obese and lean women, which may impair survival of obese women with breast cancer. Specific strategies are needed to optimize the care of obese women with or at risk of breast cancer.

Reeves GK, Pirie K, Beral V, Green J, Spencer E (2007) Bull D cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 335(7630):1134CrossRefPubMed

Lahmann PH, Hoffmann K, Allen N, Van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 111(5):762–771CrossRefPubMed

Bouchardy C, Le MG, Hill C (1990) Risk factors for breast cancer according to age at diagnosis in a French case-control study. J Clin Epidemiol 43(3):267–275CrossRefPubMed

Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL, Phillips KA (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14(7):1686–1691CrossRefPubMed

Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM (2008) Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072–4077CrossRefPubMed

Carmichael AR, Bates T (2004) Obesity and breast cancer: a review of the literature. Breast 13(2):85–92CrossRefPubMed

Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111(2):329–342CrossRefPubMed

Carmichael AR (2006) Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 113(10):1160–1166CrossRefPubMed

Enger SM, Greif JM, Polikoff J, Press M (2004) Body weight correlates with mortality in early-stage breast cancer. Arch Surg 139(9):954–958CrossRefPubMed

10.

Bouchardy C, Geneva, Switzerland (2003) Cancer incidence in five continents. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) International agency for research on cancer, vol VIII. IARC, Lyon, pp 448–449

11.

World Health Organization (WHO) (2008) WHO, global database on body mass index, BMI classification. 30-4-2008

12.

Sobin LH, Ch Wittekind (eds) (2002) TNM classification of malignant tumours. UICC, New York

13.

ICD-O International classification of diseases for oncology (1975) World Health Organization, Genève

14.

Breslow NE, Day NE (1987) Statistical methods in cancer research: the design and analysis of cohort studies, vol II. International Agency for Research on Cancer, IARC Scientific Publications no 82, Lyon

15.

Porter GA, Inglis KM, Wood LA, Veugelers PJ (2006) Effect of obesity on presentation of breast cancer. Ann Surg Oncol 13(3):327–332CrossRefPubMed

16.

Kim YA, Lee CW (2004) Effects of obesity on breast cancer stage at diagnosis in Korean women. Eur J Cancer Prev 13(1):13–17CrossRefPubMed

17.

Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL (2002) Body mass and stage of breast cancer at diagnosis. Int J Cancer 98(2):279–283CrossRefPubMed

18.

Hahn KM, Bondy ML, Selvan M, Lund MJ, Liff JM, Flagg EW, Brinton LA, Porter P, Eley JW, Coates RJ (2007) Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol 166(9):1035–1044CrossRefPubMed

19.

Cui Y, Whiteman MK, Langenberg P, Sexton M, Tkaczuk KH, Flaws JA, Bush TL (2002) Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women? J Womens Health Gend Based Med 11(6):527–536CrossRefPubMed

20.

Vona-Davis L, Howard-McNatt M, Rose DP (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 8(5):395–408CrossRefPubMed

21.

Verreault R, Brisson J, Deschenes L, Naud F (1989) Body weight and prognostic indicators in breast cancer. Modifying effect of estrogen receptors. Am J Epidemiol 129(2):260–268PubMed

22.

Maehle BO, Tretli S (1996) Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat 41(2):123–130CrossRefPubMed

23.

Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A (2006) Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer 119(7):1683–1689CrossRefPubMed

24.

Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228PubMedCrossRef

25.

Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR (1995) Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women’s Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4(4):319–326PubMed

26.

Li CI, Malone KE, Daling JR (2006) Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 17(5):695–703CrossRefPubMed

27.

Yoo K, Tajima K, Park S, Kang D, Kim S, Hirose K, Takeuchi T, Miura S (2001) Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan). Cancer Lett 167(1):57–63CrossRefPubMed

28.

Honda H, Ohi Y, Umekita Y, Takasaki T, Kuriwaki K, Ohyabu I, Yoshioka T, Yoshida A, Taguchi S, Ninomiya K, Akiba S, Nomura S, Sagara Y, Yoshida H (1999) Obesity affects expression of progesterone receptors and node metastasis of mammary carcinomas in postmenopausal women without a family history. Pathol Int 49(3):198–202CrossRefPubMed

29.

Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMed

30.

Horwitz KB, Mcguire WL (1978) Estrogen control of progesterone receptor in human breast-cancer—correlation with nuclear processing of estrogen-receptor. J Biol Chem 253(7):2223–2228PubMed

31.

Vona-Davis L, Rose DP (2007) Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14(2):189–206CrossRefPubMed

32.

Carmichael AR (2006) Obesity and prognosis of breast cancer. Obes Rev 7(4):333–340CrossRefPubMed

33.

Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS (2009) Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27(2):176–185CrossRefPubMed

34.

Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293(20):2479–2486CrossRefPubMed

35.

Reeves MJ, Newcomb PA, Remington PL, Marcus PM, MacKenzie WR (1996) Body mass and breast cancer. Relationship between method of detection and stage of disease. Cancer 77(2):301–307CrossRefPubMed

36.

Hall HI, Coates RJ, Uhler RJ, Brinton LA, Gammon MD, Brogan D, Potischman N, Malone KE, Swanson CA (1999) Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer 82(1):23–27CrossRefPubMed

37.

Hoe AL, Mullee MA, Royle GT, Guyer PB, Taylor I (1993) Breast size and prognosis in early breast cancer. Ann R Coll Surg Engl 75(1):18–22PubMed

38.

Ferrante JM, Chen PH, Crabtree BF, Wartenberg D (2007) Cancer screening in women: body mass index and adherence to physician recommendations. Am J Prev Med 32(6):525–531CrossRefPubMed

39.

Cohen SS, Signorello LB, Gammon MD, Blot WJ (2007) Obesity and recent mammography use among black and white women in the Southern Community Cohort Study (United States). Cancer Causes Control 18(7):765–773CrossRefPubMed

40.

Fontaine KR, Heo M, Allison DB (2001) Body weight and cancer screening among women. J Womens Health Gend Based Med 10(5):463–470CrossRefPubMed

41.

Wee CC, McCarthy EP, Davis RB, Phillips RS (2000) Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 132(9):697–704PubMed

42.

Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H (2002) Patient delay and stage of diagnosis among breast cancer patients in Germany—a population based study. Br J Cancer 86(7):1034–1040CrossRefPubMed

43.

Wadden TA, Anderson DA, Foster GD, Bennett A, Steinberg C, Sarwer DB (2000) Obese women’s perceptions of their physicians’ weight management attitudes and practices. Arch Fam Med 9(9):854–860CrossRefPubMed

44.

El Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W (2007) Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg 245(5):665–671CrossRefPubMed

45.

Forouhi P, Dixon JM, Leonard RC, Chetty U (1995) Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg 82(1):79–82CrossRefPubMed

46.

Munhoz AM, Montag E, Arruda EG, Aldrighi C, Gemperli R, Aldrighi JM, Ferreira MC (2006) Critical analysis of reduction mammaplasty techniques in combination with conservative breast surgery for early breast cancer treatment. Plast Reconstr Surg 117(4):1091–1103CrossRefPubMed

47.

Vilar-Compte D, Jacquemin B, Robles-Vidal C, Volkow P (2004) Surgical site infections in breast surgery: case-control study. World J Surg 28(3):242–246CrossRefPubMed

48.

Buist DS, Ichikawa L, Prout MN, Yood MU, Field TS, Owusu C, Geiger AM, Quinn VP, Wei F, Silliman RA (2007) Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care. J Clin Oncol 25(23):3428–3436CrossRefPubMed

49.

Griggs JJ, Culakova E, Sorbero ME, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH (2007) Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25(3):277–284CrossRefPubMed

50.

Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165(11):1267–1273CrossRefPubMed

Title: Impact of obesity on diagnosis and treatment of breast cancer
Authors: Carole Deglise
Christine Bouchardy
Mafalda Burri
Massimo Usel
Isabelle Neyroud-Caspar
Georges Vlastos
Pierre Olivier Chappuis
Michela Ceschi
Silvia Ess
Monica Castiglione
Elisabetta Rapiti
Helena Marieke Verkooijen
Publication date: 01-02-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0459-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer

Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis

Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo

Evaluation of malignancy-risk gene signature in breast cancer patients

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Keynote webinar | Spotlight on antibody–drug conjugates in cancer